国立がん研究センターの研究活動・成果

バイオリソースを活用した共同研究実績

共同研究実績 2015年4月1日調査時点 2016年4月1日調査時点 2017年4月1日調査時点
共同研究実施件数 160 190 225
共同研究機関数 企業 121 143 175
大学 243 272 283
その他 90 97 114

研究概要例

研究成果_がん研究センター_2016_1
研究成果_がん研究センター_2016_2

ページトップへ

バイオリソースを活用した研究成果(2010年以降、原著論文)

2017年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours.
Asano N, Yoshida A, Ichikawa H, Mori T, Nakamura M, Kawai A, Hiraoka N.
Histopathology. 70:385-393. 2017.
2Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, et al.
Oncotarget. 8:12941-12952. 2017.
3The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.
Goto M, Naito M, Saruwatari K, Hisakane K, Kojima M, Fujii S, Kuwata T, et al.
J Cancer Res Clin Oncol. 143:215-223. 2017.
4Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Hatogai K, Fujii S, Kojima T, Daiko H, Doi T, Ohtsu A, Ochiai A, et al.
BMC Cancer. 17:36. 2017.
5Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, Ishii G, et al.
Clin Cancer Res. 23:757-765. 2017.
6A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
Noro R, Ishigame T, Walsh N, Shiraishi K, Robles AI, Ryan BM, Schetter AJ, et al.
J Thorac Oncol. 12:65-76. 2017.
7Genes involved in development and differentiation are commonly methylated in cancers derived from multiple organs: A single-institutional methylome analysis using 1007 tissue specimens.
Ohara K, Arai E, Takahashi Y, Ito N, Shibuya A, Tsuta K, Kushima R, et al.
Carcinogenesis. doi: 10.1093/carcin/bgw209. [Epub ahead of print]. 2017.
8Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma.
Shimizu K, Kirita K, Aokage K, Kojima M, Hishida T, Kuwata T, Fujii S, et al.
J Cancer Res Clin Oncol. 143:321-328. 2017.
9Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy.
Yanagita T, Murata Y, Tanaka D, Motegi SI, Arai E, Daniwijaya EW, Hazama D, et al.
JCI Insight. 2:e89140. 2017.
10Infrequent mismatch repair protein loss in gallbladder cancer patients in Japan.
Yoshida H, Shimada K, Hiraoka N.
Virchows Arch. 470:109-112. 2017.

原著論文トップへ

2016年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma.
Aramaki N, Ishii G, Yamada E, Morise M, Aokage K, Kojima M, Hishida T, et al.
J Cancer Res Clin Oncol. 142:37-46. 2016.
2Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.
Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, et al.
Lung Cancer. 93:77-81. 2016.
3Genomic characterization of primary central nervous system lymphoma.
Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, et al.
Acta Neuropathol. 131:865-875. 2016.
4Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel A, Uchida S, et al.
Clin Cancer Res. 23:1220-1226. 2016.
5The difference in Ezrin-pAkt signaling axis between lepidic and papillary predominant invasive adenocarcinomas of the lung.
Hata K, Yoshida J, Udagawa H, Hashimoto H, Fujii S, Hishida T, Kuwata T, et al.
J Cancer Res Clin Oncol. 142:1421-1430. 2016.
6Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, et al.
Oncotarget. 7:47252-47264. 2016.
7Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method.
Higaki E, Kuwata T, Nagatsuma AK, Nishida Y, Kinoshita T, Aizawa M, Nitta H, et al.
Gastric Cancer. 19:63-73. 2016.
8PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma.
Hirahata M, Osaki M, Kanda Y, Sugimoto Y, Yoshioka Y, Kosaka N, Takeshita F, et al.
Cancer Med. 5:892-902. 2016.
9Tertiary Lymphoid Organs in Cancer Tissues.
Hiraoka N, Ino Y, Yamazaki-Itoh R.
Front Immunol. 7:244. 2016.
10Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma.
Hisakane K, Saruwatari K, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, et al.
J Cancer Res Clin Oncol. 142:593-600. 2016.
11Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma.
Hori S, Shimada K, Ino Y, Oguro S, Esaki M, Nara S, Kishi Y, et al.
Virchows Arch. 469:621-634. 2016.
12Effusion cytomorphology of small round cell tumors.
Ikeda K, Tsuta K.
J Cytol. 33:85-92. 2016.
13The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study.
Ito J, Asano N, Kawai A, Yoshida A.
Hum Pathol. 47:32-37. 2016.
14Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung.
Kamata T, Sunami K, Yoshida A, Shiraishi K, Furuta K, Shimada Y, Katai H, et al.
J Thorac Oncol. 11:261-265. 2016.
15Mucinous micropapillary pattern in lung adenocarcinomas: a unique histology with genetic correlates.
Kamata T, Yoshida A, Shiraishi K, Furuta K, Kosuge T, Watanabe S, Asamura H, et al.
Histopathology. 68:356-366. 2016.
16Mieap-regulated mitochondrial quality control is frequently inactivated in human colorectal cancer.
Kamino H, Nakamura Y, Tsuneki M, Sano H, Miyamoto Y, Kitamura N, Futamura M, et al.
Oncogenesis. 4:e181. 2016.
17Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.
Kanemoto K, Fukuta K, Kawai N, Tozawa K, Ochiai M, Okamoto K, Ohnami S, et al.
PLoS One. 11:e0167374. 2016.
18Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
Katsuya Y, Horinouchi H, Asao T, Kitahara S, Goto Y, Kanda S, Fujiwara Y, et al.
Lung Cancer. 99:4-10. 2016.
19Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, et al.
Gastric Cancer. 20(3):407-415. 2017.
20Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.
Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, Yoshino T, et al.
Ann Oncol. 27:127-133. 2016.
21miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma.
Kubota D, Kosaka N, Fujiwara T, Yoshida A, Arai Y, Qiao Z, Takeshita F, et al.
Sarcoma. 2016:1390571. Epub 2016.
22Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern.
Masai K, Tsuta K, Motoi N, Shiraishi K, Furuta K, Suzuki S, Asakura K, et al.
J Thorac Oncol. 11:2141-2149. 2016.
23Factors influencing the concordance of histological subtype diagnosis from biopsy and resected specimens of lung adenocarcinoma.
Matsuzawa R, Kirita K, Kuwata T, Umemura S, Matsumoto S, Fujii S, Yoh K, et al.
Lung Cancer. 94:1-6. 2016.
24Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes.
Mimaki S, Totsuka Y, Suzuki Y, Nakai C, Goto M, Kojima M, Arakawa H, et al.
Carcinogenesis. 37:817-826. 2016.
25C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, Ueno H, et al.
Pancreas. 45:110-116. 2016.
26Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma.
Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, et al.
Clin Proteomics. 13:28. 2016.
27Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung.
Naito M, Aokage K, Saruwatari K, Hisakane K, Miyoshi T, Hishida T, Yoshida J, et al.
Lung Cancer. 100:53-62. 2016.
28miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma.
Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara T, Matsuo K, Yoshida A, Kawai A, et al.
Oncogene. 35:6177-6188. 2016.
29Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, Yoshida A, et al.
Jpn J Clin Oncol. 46:31-39. 2016.
30SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R, Komatsu S, Mori T, Sekine S, Hirajima S, Yoshimoto S, Kanai Y, et al.
Hum Pathol. 49:145-155. 2016.
31Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies.
Ojima H, Yamagishi S, Shimada K, Shibata T.
World J Gastroenterol. 22:9035-9038. 2016.
32Clinicopathological, endoscopic, and molecular characteristics of the "skirt" - a new entity of lesions at the margin of laterally spreading tumors.
Osera S, Fujii S, Ikematsu H, Miyamoto H, Oono Y, Yano T, Ochiai A, et al.
Endoscopy. 48:448-455. 2016.
33Comprehensive mutation profiling of mucinous gastric carcinoma.
Rokutan H, Hosoda F, Hama N, Nakamura H, Totoki Y, Furukawa E, Arakawa E, et al.
J Pathol. 240:137-148. 2016.
34Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma.
Saito K, Arai E, Maekawa K, Ishikawa M, Fujimoto H, Taguchi R, Matsumoto K, et al.
Sci Rep. 6:28932. 2016.
35Histological differences between preoperative chemoradiotherapy and chemotherapy for rectal cancer: a clinicopathological study.
Sakuyama N, Kojima M, Kawano S, Akimoto T, Saito N, Ito M, Ochiai A.
Pathol Int. 66:273-280. 2016.
36Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, Kirita K, et al.
Lung Cancer. 91:7-14. 2016.
37Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.
Sawada G, Niida A, Uchi R, Hirata H, Shimamura T, Suzuki Y, Shiraishi Y, et al.
Gastroenterology. 150:1171-1182. 2016.
38Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, et al.
Oncologist. 21:156-164. 2016.
39The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung.
Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, et al.
J Cancer Res Clin Oncol. 142:905-912. 2016.
40Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.
Sekine S, Yamashita S, Tanabe T, Hashimoto T, Yoshida H, Taniguchi H, Kojima M, et al.
J Pathol. 239:133-138. 2016.
41Novel combination of serum microRNA for detecting breast cancer in the early stage.
Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, et al.
Cancer Sci. 107:326-34. 2016.
42Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.
Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, et al.
Nat Commun. 7:12451. 2016.
43Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, Shimada Y, et al.
J Thorac Oncol. 11:203-212. 2016.
44Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
Tanaka M, Nakajima T, Sugano K, Yoshida T, Taniguchi H, Kanemitsu Y, Nagino M, et al.
Histopathology. 69:322-328. 2016.
45Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.
Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen K, et al.
Hum Mol Genet. 25:620-629. 2016.
46CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas.
Yoshida A, Goto K, Kodaira M, Kobayashi E, Kawamoto H, Mori T, Yoshimoto S, et al.
Am J Surg Pathol. 40:313-323. 2016.
47A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.
Yoshida H, Shimada K, Kosuge T, Hiraoka N.
Virchows Arch. 468:431-439. 2016.

原著論文トップへ

2015年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Site-specific fibroblasts regulate site-specific inflammatory niche formation in gastric cancer.
Abe A, Nagatsuma AK, Higuchi Y, Nakamura Y, Yanagihara K, Ochiai A.
Gastric Cancer. 20(1):92-103. 2017.
2Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
Arai E, Gotoh M, Tian Y, Sakamoto H, Ono M, Matsuda A, Takahashi Y, et al.
Int J Cancer. 137:2589-2606. 2015.
3TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer.
Fujii S, Fujihara A, Natori K, Abe A, Kuboki Y, Higuchi Y, Aizawa M, et al.
Cancer Med. 4:1667-1678. 2015.
4Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, Nakamura T, et al.
Nat Commun. 6:6120. 2015.
5Adult-onset inflammatory myofibroblastic tumor of the stomach with a TFG-ROS1 fusion.
Fujita H, Yoshida A, Taniguchi H, Katai H, Sekine S.
Histopathology. 66:610-612. 2015.
6Identification and Characterization of CXCR4-Positive Gastric Cancer Stem Cells.
Fujita T, Chiwaki F, Takahashi RU, Aoyagi K, Yanagihara K, Nishimura T, Tamaoki M, et al.
PLoS One. 10:e0130808. 2015.
7Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis.
Fujita Y, Araya J, Ito S, Kobayashi K, Kosaka N, Yoshioka Y, Kadota T, et al.
J Extracell Vesicles. 11;4:28388. 2015.
8The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.
Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, et al.
Mol Ther. 23:717-727. 2015.
9Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.
Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K, Ochiya T.
Oncotarget. 6:3335-3345. 2015.
10Familial adenomatous polyposis-associated and sporadic pyloric gland adenomas of the upper gastrointestinal tract share common genetic features.
Hashimoto T, Ogawa R, Matsubara A, Taniguchi H, Sugano K, Ushiama M, Yoshida T, et al.
Histopathology. 67:689-698. 2015.
11Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y, Yoshida A, Yoshida M, Takahashi M, Tsuta K.
Pathol Int. 65:286-292. 2015.
12Gastrointestinal Fibroblasts Have Specialized, Diverse Transcriptional Phenotypes: A Comprehensive Gene Expression Analysis of Human Fibroblasts.
Higuchi Y, Kojima M, Ishii G, Aoyagi K, Sasaki H, Ochiai A.
PLoS One. 10:e0129241. 2015.
13Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer.
Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K.
Br J Cancer. 112:1782-1790. 2015.
14Honda Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, et al.
Sci Rep. 5:15921. 2015.
15Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer.
Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, Katai H, et al.
Oncogene. 34:1196-1206. 2015.
16ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status.
Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, Kushima R.
World J Gastroenterol. 21:2159-2168. 2015.
17Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. Carcinogenesis 36:616-621, 2015.
Iwakawa R, Kohno T, Totoki Y, Shibata T, Tsuchihara K, Mimaki S, Tsuta K, et al.
Carcinogenesis. 36:616-621. 2015.
18Ciliated muconodular papillary tumors of the lung: a clinicopathologic analysis of 10 cases.
Kamata T, Yoshida A, Kosuge T, Watanabe S, Asamura H, Tsuta K.
Am J Surg Pathol. 39:753-760. 2015.
19Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K.
Lung Cancer. 88:154-159. 2015.
20Assessment of elasticity of colorectal cancer tissue, clinical utility, pathological and phenotypical relevance.
Kawano S, Kojima M, Higuchi Y, Sugimoto M, Ikeda K, Sakuyama N, Takahashi S, et al.
Cancer Sci. 106:1232-1239. 2015.
21Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, et al.
Clin Lung Cancer. 16:385-390. 2015.
22MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H, Ochiai A.
PLoS One. 10:e0118220. 2015.
23Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H, Ishii G, Yoh K, Neri S, Morise M, Umemura S, Matsumoto S, et al.
J Cancer Res Clin Oncol. 141:1163-1170. 2015.
24 Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia.
Machiela MJ, Hsiung CA, Shu XO, Seow WJ, Wang Z, Matsuo K, Hong YC, et al.
Int J Cancer. 137:311-319. 2015.
25Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, et al.
J Biol Chem. 290:17495-17504. 2015.
26Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum.
Matsubara A, Ogawa R, Suzuki H, Oda I, Taniguchi H, Kanai Y, Kushima R, et al.
Br J Cancer. 112:1398-1404. 2015.
27Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y, Umemura S, Ishii G, Tsuta K, Matsumoto S, Aokage K, Hishida T, et al.
J Cancer Res Clin Oncol. 141:2159-2170. 2015.
28Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.
Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Furuse J, et al.
Pancreas. 44:756-763. 2015.
29Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T, Asamura H, et al.
J Thorac Oncol. 10:844-851. 2015.
30Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, Ochiai A.
Gastric Cancer. 18:227-238. 2015.
31Genomic spectra of biliary tract cancer.
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, et al.
Nat Genet. 47:1003-1010. 2015.
32Tumour multifocality and grade predict intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma without a history of bladder cancer. Jpn J Clin Oncol 45:488-493, 2015.
Narukawa T, Hara T, Arai E, Komiyama M, Kawahara T, Kanai Y, Fujimoto H.
Jpn J Clin Oncol. 45:488-493. 2015.
33A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y, Kuwata T, Nitta H, Dennis E, Aizawa M, Kinoshita T, Ohtsu A, et al.
Gastric Cancer. 18:458-466. 2015.
34Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma.
Oguro S, Esaki M, Kishi Y, Nara S, Shimada K, Ojima H, Kosuge T.
Ann Surg Oncol. 22:1915-1924. 2015.
35Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.
Oguro S, Ino Y, Shimada K, Hatanaka Y, Matsuno Y, Esaki M, Nara S, et al.
Cancer Sci. 106:1750-1760. 2015.
36An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. , 2015.
Robles AI, Arai E, Mathé EA, Okayama H, Schetter AJ, Brown D, Petersen D, et al.
J Thorac Oncol. 10:1037-1048. 2015.
37Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer.
Ryan BM, Robles AI, McClary AC, Haznadar M, Bowman ED, Pine SR, Brown D, et al.
Cancer Res. 75:566-575. 2015.
38Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H, Chiku S, et al.
Cancer Res. 75:2264-2271. 2015.
39Lysine Demethylase LSD1 Coordinates Glycolytic and Mitochondrial Metabolism in Hepatocellular Carcinoma Cells.
Sakamoto A, Hino S, Nagaoka K, Anan K, Takase R, Matsumori H, Ojima H, et al.
Cancer Res. 75:1445-1456. 2015.
40Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.
Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, et al.
J Natl Cancer Inst. 107(12):djv279. 2015.
41Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. .
Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, Yoshino T, et al.
Jpn J Clin Oncol. 45:43-48. 2015.
42Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Sato T, Soejima K, Arai E, Hamamoto J, Yasuda H, Arai D, Ishioka K, et al.
Oncol Rep. 34:1137-1145. 2015.
43Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers.
Sekiguchi M, Kushima R, Oda I, Suzuki H, Taniguchi H, Sekine S, Fukagawa T, et al.
J Gastroenterol. 50:424-434. 2015.
44Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion.
Sekiguchi M, Sekine S, Sakamoto T, Otake Y, Nakajima T, Matsuda T, Taniguchi H, et al.
J Gastroenterol. 50:1184-1189. 2015.
45Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.
Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, et al.
Mol Cancer Ther. 14:1985-1993. 2015.
46KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.
Simó-Riudalbas L, Pérez-Salvia M, Setien F, Villanueva A, Moutinho C, Martínez-Cardús A, Moran S, et al.
Cancer Res. 75:3936-3945. 2015.
47A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts.
Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, et al.
Gastroenterology. 149:1501-1510. 2015.
48Pancreatic perfusion data and post-pancreaticoduodenectomy outcomes.
Sugimoto M, Takahashi S, Kobayashi T, Kojima M, Gotohda N, Satake M, Ochiai A, et al.
J Surg Res. 194:441-449. 2015.
49Peripheral opioid antagonist enhances the effect of anti-tumor drug by blocking a cell growth-suppressive pathway in vivo.
Suzuki M, Chiwaki F, Sawada Y, Ashikawa M, Aoyagi K, Fujita T, Yanagihara K, et al.
PLoS One. 10:e0123407. 2015.
50HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, Furuta K, et al.
Lung Cancer. 87:14-22. 2015.
51Ezrin-expressing lung adenocarcinoma cells and podoplanin-positive fibroblasts form a malignant microenvironment.
Suzuki S, Ishii G, Matsuwaki R, Neri S, Hashimoto H, Yamauchi C, Aokage K, et al.
J Cancer Res Clin Oncol. 141:475-484. 2015.
52Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth.
Takahashi A, Ishii G, Neri S, Yoshida T, Hashimoto H, Suzuki S, Umemura S, et al.
Oncotarget. 6:9531-9541. 2015.
53Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.
Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, et al.
BMC Cancer. 15:718. 2015.
54 Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.
Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, Suzuki M, et al.
Sci Rep. 5:18425. 2015.
55Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy.
Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, Tamaoki M, et al.
PLoS One. 10:e0143804. 2015.
56Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.
Terai H, Soejima K, Yasuda H, Sato T, Naoki K, Ikemura S, Arai D, et al.
Int J Oncol. 46:430-436. 2015.
57Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung.
Udagawa H, Ishii G, Morise M, Umemura S, Matsumoto S, Yoh K, Niho S, et al.
J Cancer Res Clin Oncol 141:1417-1425. 2015.
58ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.
Watanabe T, Ueno H, Watabe Y, Hiraoka N, Morizane C, Itami J, Okusaka T, et al.
Br J Cancer. 112:704-713. 2015.
59Biomarker Expression and Druggable Gene Alterations for Development of an Appropriate Therapeutic Protocol for Pulmonary Adenosquamous Carcinoma.
Watanabe Y, Shiraishi K, Takahashi F, Yoshida A, Suzuki K, Asamura H, Takeuchi M, et al.
Histopathology. 66:939-948. 2015.
60Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S, Horinouchi H, Katsui Taniyama T, Nakamichi S, Kitazono S, Mizugaki H, Kanda S, et al.
Int J Radiat Oncol Biol Phys 91:140-148. 2015.
61Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer.
Yagishita S, Horinouchi H, Sunami KS, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, et al.
Cancer Sci. 106:1402-1407. 2015.
62Investigating endoscopic features of sessile serrated adenomas/polyps by using narrow-band imaging with optical magnification.
Yamada M, Sakamoto T, Otake Y, Nakajima T, Kuchiba A, Taniguchi H, Sekine S, et al.
Gastrointest Endosc. 82:108-117. 2015.
63Epigenetic clustering of gastric carcinomas based on DNA methylation profiles at the precancerous stage: its correlation with tumor aggressiveness and patient outcome.
Yamanoi K, Arai E, Tian Y, Takahashi Y, Miyata S, Sasaki H, Chiwaki F, et al.
Carcinogenesis. 36:509-520. 2015.
64Decreased expression of gastric gland mucin-specific glycan α1,4-linked N-acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach.
Yamanoi K, Sekine S, Higuchi K, Kushima R, Nakayama J.
Histopathology. 67:898-904. 2015.
65Spread of tumor microenvironment contributes to colonic obstruction through subperitoneal fibroblast activation in colon cancer.
Yokota M, Kojima M, Higuchi Y, Nishizawa Y, Kobayashi A, Ito M, Saito N, et al.
Cancer Sci. 106:466-474. 2015.
66TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, et al.
Br J Cancer. 113:1244-1248. 2015.
67Frequent MED12 mutations in phyllodes tumours of the breast.
Yoshida M, Sekine S, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, et al.
Br J Cancer. 112:1703-1708. 2015.

原著論文トップへ

2014年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1High Mobility Group Box1 (HMGB1) released from cancer cells induces the expression of pro-inflammatory cytokines in peritoneal fibroblasts.
Abe A, Kuwata T, Yamauchi C, Higuchi Y, Ochiai A.
Pathol Int. 64:267-275. 2014.
2Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.
Arai E, Sakamoto H, Ichikawa H, Totsuka H, Chiku S, Gotoh M, Mori T, et al.
Int J Cancer. 135:1330-1342. 2014.
3Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, et al.
Hepatology. 59:1427-1434. 2014.
4Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells.
Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, et al.
Stem Cells. 32:959–973. 2014.
5Zinc finger protein 185 is a liver metastasis-associated factor in colon cancer patients.
Furukawa D, Chijiwa T, Matsuyama M, Mukai M, Matsuo EI, Nishimura O, Kawai K, et al.
Mol Clin Oncol. 2:709-713. 2014.
6Comprehensive exploration of novel chimeric transcripts in clear cell renal cell carcinomas using whole transcriptome analysis.
Gotoh M, Ichikawa H, Arai E, Chiku S, Sakamoto H, Fujimoto H, Hiramoto M, et al.
Genes Chromosomes Cancer. 53:1018-1032. 2014.
7Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.
Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira M, et al.
Ann Oncol. 25:1973-1979. 2014.
8Frequent presence of gastric-type epithelial cells in the duodenal bulb: An immunohistochemical study.
Hashimoto T, Sekine S, Matsubara A, Taniguchi H, Kushima R.
Pathol Int. 64:631-633. 2014.
9Potential biomarker for human uterine leiomyosarcoma.
Hayashi T, Horiuchi A, Aburatani H, Ishiko O, Yaegashi N, Kanai Y, Zharhary D, et al.
J Clin Med Res. 6:392-394. 2014.
10Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T, Horiuchi A, Sano K, Hiraoka N, Ichimura T, Sudo T, Ishiko O, et al.
Tumori. 100:e99-e106. 2014.
11Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma.
Hori M, Takahashi M, Hiraoka N, Yamaji T, Mutoh M, Ishigamori R, Furuta K, et al.
Clin Transl Gastroenterol. 5:e53. 2014.
12 A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y, Yamada K, Yugawa T, Ohno S, Hiraoka N, Esaki M, Shibata T, et al.
Carcinogenesis. 35:1840-1846. 2014.
13Consistent absence of HER2 expression, regardless of HER2 amplification status, in neuroendocrine carcinomas of the stomach.
Ishida M, Sekine S, Taniguchi H, Fukagawa T, Katai H, Kushima R.
Histopathology. 64:1027-1031. 2014.
14Early venous return in hepatic angiomyolipoma due to an intratumoral structure resembling an arteriovenous fistula.
Iwao Y, Ojima H, Onaya H, Sakamoto Y, Kishi Y, Nara S, Esaki M, et al.
Hepatol Res. 44:700-706. 2014.
15Mucinous breast carcinoma with a lobular neoplasia component: A subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation.
Jimbo K, Tsuda H, Yoshida M, Miyagi-Maeshima A, Sasaki-Katsurada Y, Asaga S, Hojo T, et al.
Pathol Int. 64:217-223. 2014.
16Multilayer-omics analyses of human cancers: exploration of biomarkers and drug targets based on the activities of the International Human Epigenome Consortium.
Kanai Y, Arai E.
Front Genet. 5:24. 2014.
17Wide local extension and higher proliferation indices are characteristic features of symptomatic lobular neoplasias (LNs) and LNs with an early invasive component.
Katsurada Y, Yoshida M, Maeshima AM, Ikeda K, Shibata T, Kinoshita T, Matsubara O, et al.
Histopathology. 64:994-1003. 2014.
18 Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, et al.
Ann Oncol. 25:138-142. 2014.BRAF変異陽性肺がんの病理組織学的解析を行い、その特徴を明らかにした。
19 Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.
Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T.
Ann Surg Oncol. 21:2882-2888. 2014.
20 MicroRNA expression and functional profiles of osteosarcoma.
Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, Kawai A, et al.
Oncology 86:94-103. 2014.骨肉腫のマイクロRNA発現をプロファイルした。
21 RET and other genes: therapeutic targets in lung adenocarcinoma.
Kohno T, Tsuchihara K, Ogiwara H, Ichikawa H.
Lung Cancer Manag. 3:219-226. 2014.
22 Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis.
Kojima M, Higuchi Y, Yokota M, Ishii G, Saito N, Aoyagi K, Sasaki H, et al.
PLoS One. 9:e88018. 2014.
23 Marked lymphovascular invasion, progesterone receptor negativity and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J, Kanomata N, Shimo T, Yamashita T, Aogi K, Nishimura R, Shimizu C, et al.
Breast Cancer. 21:214-222. 2014.リンパ管侵襲、PgR陰性、Ki67LI 高値が術後薬物療法としてtamoxifen単独療法を受けた乳癌患者の予後因子となる可能性が示唆された。
24NEK9-dependent proliferation of cancer cells lacking functional p53.
Kurioka D, Takeshita F, Tsuta K, Sakamoto H, Watanabe S, Matsumoto K, Watanabe M, et al.
Sci Rep. 4:6111. 2014.
25 Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program.
Kushima R, Kuwata T, Yao T, Kuriki H, Hashizume K, Masuda S, Tsuda H, et al.
Virchows Arch. 464:539-545. 2014.
26 Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases.
Masai K, Nakagawa K, Yoshida A, Sakurai H, Watanabe S, Asamura H, Tsuta K.
Lung Cancer. 86:318-323. 2014.
27 Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Masuda M, Chen WY, Miyanaga A, Nakamura Y, Kawasaki K, Sakuma T, Ono M, et al.
Mol Cell Proteomics. 13:1429-1438. 2014.逆相タンパク質マイクロアレイを開発し、リン酸化抗体を用いてソラフェニブに抵抗性をもつ細胞株のリン酸化タンパク質をプロファイルした。
28 Intraductal dissemination of papillary adenocarcinoma of the ampulla of Vater in the pancreatic duct.
Matsubara A, Nara S, Sekine S, Ojima H, Kosuge T, Shimada K, Kushima R, et al.
Pathol Int. 64:39-44. 2014.
29 Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.
Matsubara A, Sekine S, Ogawa R, Yoshida M, Kasamatsu T, Tsuda H, Kanai Y.
Am J Surg Pathol. 38:370-376. 2014.
30 Immunophenotypic features of metastatic lymph node tumors to predict recurrence in N2 lung squamous cell carcinoma.
Matsuwaki R, Ishii G, Zenke Y, Neri S, Aokage K, Hishida T, Yoshida J, et al.
Cancer Sci. 105:905-911. 2014.
31Novel use for an EGFR mutation-specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia.
Mimori T, Kobayashi S, Tanaka A, Sasada S, Yoshida A, Izumo T, Sasaki N, et al.
Histopathology. 66:816-823. 2015.
32Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
Mizukami T, Shiraishi K, Shimada Y, Ogiwara H, Tsuta K, Ichikawa H, Sakamoto H, et al.
J Thorac Oncol. 9(5):622-30. 2014.RET融合陽性肺がんのゲノム解析を行い、発生機構を推察した。
33 Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, et al.
Nat Commun. 5:3393. 2014.
34Hepatolithiasis Subdivision of Intractable Hepatobiliary Diseases Study Group of Japan (Chairman, Hirohito Tsubouchi). Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)".
Nakanuma Y, Sato Y, Ojima H, Kanai Y, Aishima S, Yamamoto M, Ariizumi S, et al.
Int J Clin Exp Pathol. 7:3112-3122. 2014.
35 Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, et al.
Clin Cancer Res. 20:3087-3093. 2014.肺腺がん100例の発現解析を行い、新しい治療標的を同定した。
36Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S, Ushijima K, Yamaguchi T, Sasajima Y, Tsuda H, Kasamatsu T, Kage M, et al.
Gynecol Oncol. 132:703-708. 2014.
37Circulating exosomal miRNAs involved in colon cancer.
Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, et al.
PLoS One. 9:e92921. 2014.大腸がん患者血清中のエクソソームから特異的に検出されるマイクロRNAを同定し、診断マーカー候補として報告した。
38 PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, Minegishi M, et al.
Proc Natl Acad Sci. 111:E2404-E2413. 2014.膵臓がんの中でも稀な膵神経内分泌腫瘍 新規がん抑制遺伝子を発見 悪性度など予後予測と、有効な治療法の選択が可能に
39 The Expression of Four Genes as a Prognostic Classifier for Stage I Lung Adenocarcinoma in 12 Independent Cohorts.
Okayama H, Schetter AJ, Ishigame T, Robles AI, Kohno T, Yokota J, Takenoshita S, et al.
Cancer Epidemiol Biomarkers Prev. 23:2884-2894. 2014.
40 Emerging drugs for biliary cancer.
Okusaka T, Ojima H, Morizane C, Ikeda M, Shibata T.
Expert Opin Emerg Drugs. 19:11-24. 2014.
41 Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.
Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, Yoshida M, et al.
Sci Signal. 7:ra63. 2014.
42Knowledge discovery for pancreatic cancer using inductive logic programming.
Qiu Y, Shimada K, Hiraoka N, Maeshiro K, Ching WK, Aoki-Kinoshita KF, Furuta K.
IET Syst Biol. 8:162-168. 2014.
43 MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, et al.
Cancer Discov. 4:292-303. 2014.肺小細胞がんのゲノム解析を行い、新しいがん抑制遺伝子を同定した。
44A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.
Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, et al.
Clin Cancer Res. 20:4784-4793. 2014.
45Optimal fixation for total preanalytic phase evaluation in pathology laboratories: a comprehensive study including immunohistochemistry, DNA, and mRNA assays.
Sato M, Kojima M, Nagatsuma AK, Nakamura Y, Saito N, Ochiai A.
Pathol Int. 64:209-216. 2014.
46 Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease.
Sato T, Arai E, Kohno T, Takahashi Y, Miyata S, Tsuta K, Watanabe S, et al.
Int J Cancer. 135:319-334. 2014.
47Histopathological characteristics of hypervascular cholangiocellular carcinoma as an early stage of cholangiocellular carcinoma.
Sato Y, Ojima H, Onaya H, Mori T, Hiraoka N, Kishi Y, Nara S, et al.
Hepatol Res. 44:1119-1129. 2014.
48Hepatolithiasis Subdivision of Intractable Hepatobiliary Diseases Study Group of Japan (Chairman, Hirohito Tsubouchi). Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia.
Sato Y, Sasaki M, Harada K, Aishima S, Fukusato T, Ojima H, Kanai Y, et al.
J Gastroenterol. 49:64-72. 2014.
49 Risk of recurrent gastric cancer after endoscopic resection with a positive lateral margin.
Sekiguchi M, Suzuki H, Oda I, Abe S, Nonaka S, Yoshinaga S, Taniguchi H, et al.
Endoscopy. 46:273-278. 2014.
50Frequent lack of GNAS mutations in colorectal adenocarcinoma associated with GNAS-mutated villous adenoma.
Sekine S, Ogawa R, Oshiro T, Kanemitsu Y, Taniguchi H, Kushima R, Kanai Y.
Genes Chromosomes Cancer. 53:366-372. 2014.大腸絨毛腺腫に伴う浸潤癌におけるGNAS遺伝子変異の解析
51 Histological analysis suggests an invasion-independent metastatic mechanism in alveolar soft part sarcoma.
Setsu N, Yoshida A, Takahashi F, Chuman H, Kushima R.
Hum Pathol. 45:137-142. 2014.
52 Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Shoji H, Morizane C, Hiraoka N, Kondo S, Ueno H, Ohno I, Shimizu S, et al.
Jpn J Clin Oncol. 44:324-330. 2014.
53Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
Soma S, Tsuta K, Takano T, Hatanaka Y, Yoshida A, Suzuki K, Asamura H, et al.
Pathol Res Pract 210:155-160. 2014.
54 Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas.
Sugimoto M, Mitsunaga S, Yoshikawa K, Kato Y, Gotohda N, Takahashi S, Konishi M, et al.
Eur J Cancer. 50:1900-1908. 2014.
55What is the nature of pancreatic consistency? Assessment of the elastic modulus of the pancreas and comparison with tactile sensation, histology, and occurrence of postoperative pancreatic fistula after pancreaticoduodenectomy.
Sugimoto M, Takahashi S, Kojima M, Gotohda N, Kato Y, Kawano S, Ochiai A, et al.
Surgery. 156:1204-1211. 2014.
56 Analysis of gene expression profiles of soft tissue sarcoma using a combination of knowledge-based filtering with integration of multiple statistics.
Takahashi A, Nakayama R, Ishibashi N, Doi A, Ichinohe R, Ikuyo Y, Takahashi T, et al.
PLoS One. 9:e106801. 2014.
57Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T.
Jpn J Clin Oncol. 44:570-578. 2014.
58 Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Takahashi H, Sai K, Saito Y, Kaniwa N, Matsumura Y, Hamaguchi T, Shimada Y, et al.
PLoS One. 9:e105160. 2014.
59 Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.
Takahashi N, Yamada Y, Furuta K, Honma Y, Iwasa S, Takashima A, Kato K, et al.
Br J Cancer. 110:2716-2727. 2014.血清HGF、epiregulinの高値症例では抗EGFR抗体の効果が得られ難い。
60 Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, et al.
Cancer Sci. 105:1254-1260. 2014.
61Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses.
Taniyama TK, Nokihara H, Tsuta K, Horinouchi H, Kanda S, Fujiwara Y, Yamamoto N, et al.
Clin Lung Cancer. 15:244-247. 2014.
62 Global PROTOMAP profiling to search for biomarkers of early-recurrent hepatocellular carcinoma.
Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, et al.
J Proteome Res. 13:4847-4858. 2014.
63 p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2.
Tatsumori T, Tsuta K, Masai K, Kinno T, Taniyama T, Yoshida A, Suzuki K, et al.
Appl Immunohistochem Mol Morphol. 22:377-382. 2014.
64 Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes.
Tian Y, Arai E, Gotoh M, Komiyama M, Fujimoto H, Kanai Y.
BMC Cancer. 14:772. 2014.
65Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody.
Toriyama A, Mori T, Sekine S, Yoshida A, Hino O, Tsuta K.
Histopathology. 65:465-472. 2014.
66Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.
Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, et al.
Nat Genet. 46:1267-1273. 2014.
67 Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma.
Totoki Y, Yoshida A, Hosoda F, Nakamura H, Hama N, Ogura K, Yoshida A, et al.
Genome Res. 24:1411-1420. 2014.
68Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation.
Tsuta K, Kawago M, Yoshida A, Sekine S, Asamura H, Furuta K, Kushima R.
Lung Cancer. 85:12-18. 2014.
69 RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, Furuta K, Kushima R.
Br J Cancer. 110:1571-1578. 2014.RET融合陽性肺がんの病理組織学的解析を行い、その特徴を明らかにした。
70 Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, Niho S, et al.
J Thorac Oncol. 9:1324-1331. 2014.
71 Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.
Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, et al.
Hum Mol Genet. 23:6616-6633. 2014.
72 Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma.
Watabe Y, Mori T, Yoshimoto S, Nomura T, Shibahara T, Yamada T, Honda K.
Cancer Med. 3:613-622. 2014.唾液腺がんの予後予測因子を同定し、ACTN4の遺伝子増幅が独立した予後因子であることを明らかにした。
73 Clinicopathologic features and computed tomographic findings of 52 surgically resected adenosquamous carcinomas of the lung.
Watanabe Y, Tsuta K, Kusumoto M, Yoshida A, Suzuki K, Asamura H, Tsuda H.
Ann Thorac Surg. 97:245-252. 2014.
74Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1.
Yamada M, Fukagawa T, Nakajima T, Asada K, Sekine S, Yamashita S, Okochi-Takada E, et al.
Gastric Cancer 17:750-756. 2014.
75 Different histological status of gastritis in superficial adenocarcinoma of the esophagogastric junction.
Yamada M, Kushima R, Oda I, Mojtahed K, Nonaka S, Suzuki H, Yoshinaga S, et al.
Jpn J Clin Oncol. 44:65-71. 2014.
76A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.
Yamamoto Y, Hiraoka N, Goto N, Rin Y, Miura K, Narumi K, Uchida H, et al.
J Control Release 192:284-293. 2014.
77Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma.
Yamazaki K, Masugi Y, Effendi K, Tsujikawa H, Hiraoka N, Kitago M, Shinoda M, et al.
Lab Invest. 94:683-691. 2014.
78BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, Oashi K, et al.
Melanoma Res. 25:9-14. 2015.
79 Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Yoshida A, Tsuta K, Wakai S, Arai Y, Asamura H, Shibata T, Furuta K, et al.
Mod Pathol. 27:711-720. 2014.ROS1融合陽性肺がんの病理組織学的解析を行い、診断法を提案した。
80Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H.
Virchows Arch. 465:145-154. 2014.
81Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen.
Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, et al.
Nat Commun. 5:3591. 2014.

原著論文トップへ

2013年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma.
Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, et al.
Cancer Res 73:3821-3832. 2013.早期肺腺がん100例の発現解析を行い、予後予測マーカーを同定した。
2KRAS mutation in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.
Akiyoshi K, Yamada Y, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y, et al.
Anticancer Res. 33:2129-2134. 2013.大腸がんのKRAS変異検出率はダイレクトシークエンスとHRMAでほぼ同等。
3 Signatures of mutational processes in human cancer.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio S, Behjati S, Biankin AV, Bignell GR, et al.
Nature. 500:415-421. 2013.
4Technical considerations for analyzing EMT-MET data from surgical samples.
Aoyagi K, Tamaoki M, Nishimura T, Sasaki H.
Cancer Lett 341:105-110. 2013.
5 Mouse model fro ROS1-rearranged lung cancer.
Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, et al.
PLoS One. 8:e56010. 2013.肺がんにおけるROS1-EZR融合遺伝子の同定と動物モデルの作製
6Diagnostic markers of urothelial cancer based on DNA methylation analysis.
Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, Jones PA, et al.
BMC Cancer. 13:275. 2013.
7Intraperitoneal delivery of a small interfering RNA targeting NEDD1 prolongs the survival of scirrhous gastric cancer model mice.
Fujita T, Yanagihara K, Takeshita F, Aoyagi K, Takigahira M, Chiwaki F, Fukagawa T, et al.
Cancer Sci. 104:214-222. 2013.
8 Immunohistochemical actinin-4 expression in infiltrating gliomas:association with WHO grade and differentiation.
Fukushima S, Yoshida A, Honda K, Maeshima AM, Narita Y, Yamada T, Shibui S, et al.
Brain Tumor Pathol 31:11-16. 2013.グリオーマの組織学的悪性度に相関するタンパク質を同定し、バイオマーカーとしての有用性を検討した、
9MiR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells.
Gailhouste L, Gomez-Santos L, Kitagawa N, Kawaharada K, Thirion M, Kosaka N, Takahashi R, et al.
Hepatology. 58:1153-1165. 2013.
10Interactomic approach for evaluating nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma.
Haga A, Ogawara Y, Kubota D, Kitabayashi I, Murakami Y, Kondo T.
Electrophoresis. 34:1670-1678. 2013.Ewing肉腫における予後不良バイオマーカーnucleophosminの結合タンパク質を質量分析で網羅的に調べることで機能的な役割に迫った。
11Histological factors for accurately predicting first locoregional recurrence of invasive ductal carcinoma of the breast.
Hasebe T, Iwasaki M, Hojo T, Shibata T, Kinoshita T, Tsuda H.
Cancer Sci. 104:1252-1261. 2013.
12 Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.
Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N, Yamada T.
Jpn J Clin Oncol. 43:103-109. 2013.
13 Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
Ichinokawa H, Ishii G, Nagai K, Kawase A, Yoshida J, Nishimura M, Hishida T, et al.
Hum Pathol. 44:2636-2642. 2013.
14 Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer.
Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, Kanai Y, et al.
PLoS One. 8:e55146. 2013.
15Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.
Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N.
Br J Cancer. 108:914-923. 2013.
16 Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis.
Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, Katai H, et al.
Am J Surg Pathol 37:949-959. 2013.
17Classification of gastric cancer subtypes using ICA, MLR and Bayesian network.
Ishii H, Sasaki H, Aoyagi K, Yamazaki T. Classification of gastric cancer subtypes using ICA MLR and Bayesian network.
Stud Health Technol Inform. 192:1014. 2013.
18EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.
Ito Y, Yamada Y, Asada K, Ushijima T, Iwasa S, Kato K, Hamaguchi T, et al.
J Cancer Res Clin Oncol 139:1391-1396. 2013.大腸がんのEGFR細胞外ドメイン変異の頻度は少なく、cetuximabの効果との相関もなさそう。
19 Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.
Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, Tsuta K, et al.
Genes Chromosomes Cancer. 52:802-816. 2013.肺小細胞がん50例のゲノム解析を行い、治療標的となる増幅遺伝子を同定した。
20Sentinel and nonsentinel lymph node assessment using a combination of one-step nucleic acid amplification and conventional histological examination.
Jimbo K, Kinoshita T, Suzuki J, Asaga S, Hojo T, Yoshida M, Tsuda H.
Breast. 22:1194-1199. 2013.
21Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma.
Kimura K, Ojima H, Kubota D, Sakumoto M, Nakamura Y, Tomonaga T, Kosuge T, et al.
J Proteomics. 78:362-373. 2013.
22Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma.
Kinoshita T, Ishii G, Hiraoka N, Hirayama S, Yamauchi C, Aokage K, Hishida T, et al.
Cancer Sci. 104:409-415. 2013.
23Identification of biological properties of intralymphatic tumor related to the development of lymph node metastasis in lung adenocarcinoma.
Kirita K, Ishii G, Matsuwaki R, Matsumura Y, Umemura S, Matsumoto S,Yoh K; Niho S, et al.
PLoS One. 8:e83537. 2013.リンパ管内腫瘍塞栓像の病理像とリンパ節転移との相関を検討した結果、CD204TAMsの動員が転移巣形成と相関していた。
24Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma.
Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T, Totoki Y, et al.
Cancer Sci. 104:543-551. 2013.肝がんにおけるmiRNA制御分子群の発現異常解析
25 Pulmonary neuroendocrine tumors with nuclear inclusion.
Kobayashi S, Tsuta K, Sekine S, Yoshida A, Sasaki N, Shibuki Y, Sakurai H, et al.
Pathol Res Pract 209:574-577. 2013.
26RET fusion gene: translation to personalized lung cancer therapy.
Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K.
Cancer Sci. 104:1396-1400. 2013.
27Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.
Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, Ueno H, et al.
Int J Clin Oncol. 18:207-213. 2013.
28 Gastric adenocarcinoma of the fundic gland type shares common genetic and phenotypic features with pyloric gland adenoma.
Kushima R, Sekine S, Matsubara A, Taniguchi H, Ikegami M, Tsuda H.
Pathol Int. 63:318-325. 2013.
29Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy.
Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, Igaki H, et al.
Cancer Sci. 104:1045-1051. 2013.血清のsIL6Rが、食道がんの術前化学放射線療法の効果予測血清マーカーになり得ることを見出した。(食道がん術前化学療法患者において、術前血清中のsIL6Rの濃度が低い方が、治療効果が高く、予後が良い。術前化学療法ではこの効果は認められない。)
30Pleuroscopic punch biopsy using insulated-tip diathermic knife-2 for the diagnosis of desmoplastic malignant mesothelioma.
Masai K, Sasada S, Izumo T, Taniyama T, Nakamura Y, Chavez C, Sakurai H, et al.
J Bronchology Interv Pulmonol 20:345-348. 2013.
31 Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas.
Masai K, Tsuta K, Kawago M, Tatsumori T, Kinno T, Taniyama T, Yoshida A, et al.
Appl Immunohistochem Mol Morphol. 21:292-297. 2013.
32 Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum.
Matsubara A, Sekine S, Kushima R, Ogawa R, Taniguchi H, Tsuda H, Kanai Y.
J Pathol 229:579-587. 2013.
33 Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumors.
Matsubara A, Sekine S, Yoshida M, Yoshida A, Taniguchi H, Kushima R, Tsuda H, et al.
Histopathology. 62:657-661. 2013.
34Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis.
Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, Saito Y, et al.
Gastroenterology. 145:1300-1311. 2013.
35Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours.
Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, Miyamoto A, et al.
Ann Oncol. 24:84-90. 2013.
36Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J
Nakagawa T, Hara T, Kawahara T, Ogata Y, Nakanishi H, Komiyama M, Arai E, et al.
J Urol. 189:1275-1281. 2013.
37 Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma.
Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, Furuta K, et al.
J Clin Pathol 66:705-707. 2013.
38Cancer-initiating cell marker-positive cells generate metastatic tumors that recapitulate the histology of the primary tumors.
Nishijima N, Ishii G, Nagai K, Atsumi N, Aokage K, Tokunaga Y, Ichinokawa H, et al.
Pathol Int. 63:94-101. 2013.扁平上皮癌の癌幹細胞マーカーでありポドプラニン発現を原発巣と転移巣で比較し、同様の発現パターンを示したことを報告した。
39Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.
Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, Kushima R, et al.
Br J Cancer. 108:951-958. 2013.
40 New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC-in situ hybridization assay.
Nitta H, Tsuta K, Yoshida A, Ho SN, Kelly BD, Murata LB, Kosmeder J, et al.
J Thorac Oncol. 8:1019-1031. 2013.
41Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, et al.
Ann Oncol. 24:2594-600. 2013.I期肺腺がんの予後予測因子を同定し、I期術後補助化学療法のバイオマーカーとしての可能性を報告した。
42 Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma.
Oguro S, Shimada K, Ino Y, Esaki M, Nara S, Kishi Y, Kosuge T, et al.
Am J Surg Pathol 37:1030-1038. 2013.
43 SOX10 is a novelmarker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis.
Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, Watabe Y, et al.
Mod Pathol. 26:1041-1050. 2013.SOX10分子が唾液腺の発生段階から発現し、腺房、線条導管分化形質を示すことを明らかとした。また、形態学的に診断が困難な唾液腺腫瘍の診断マーカーとして有用であることを明らかとした。
44 A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, et al.
Cancer Res 73:5508-5518. 2013.100例の肺腺がんの免疫染色解析を行い、分子標的治療対象外の肺がんに対する新しい治療法を示唆した。
45 Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following ssurgery and radiotherapy for brain metastasis.
Okita Y, Narita Y, Suzuki T, Arita H, Yonemori K, Kinoshita T, Fujiwara Y, et al.
Mol Clin Oncol. 1:995-1001. 2013.
46 Prognostic immunophenotypic studies in stage I lung squamous cell carcinoma: Utility of combining analysis of both cancer cell phenotype and cancer associated fibroblast phenotype.
Ono S, Ishii G, Nagai K, Takuwa T, Yoshida J, Nishimura M, Hishida T, et al.
Chest. 143:963-970. 2013.I期扁平上皮癌における予後因子として、がん細胞およびCAFの性状の重要性を示唆している。
47Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
Otsuka T, Morizane C, Nara S, Ueno H, Kondo S, Shimada K, Kosuge T, et al.
Pancreas. 42:889-892. 2013.
48 Genetic factors related to gastric-cancer susceptibility identified using a genomewide association study.
Saeki N, Ono H, Sakamoto H, Yoshida T.
Cancer Sci. 104:1-8. 2013.
49The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.
Saito Y, Suzuki H, Imaeda H, Matsuzaki J, Hirata K, Tsugawa H, Hibino S, et al.
Int J Cancer. 132:1751-1760. 2013.
50 DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma.
Sato T, Arai E, Kohno T, Tsuta K, Watanabe S, Soejima K, Betsuyaku T, et al.
PLoS One. 8:e59444. 2013.肺の前がん段階において既に、がんが確立した後の予後と相関するDNAメチル化プロファイルが成立しており、そのような前がん段階におけるDNAメチル化異常が、肺腺がんへの進展に伴って特定の遺伝子の発現異常に帰結し、がんの悪性度を規定することを示した。
51Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case.
Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, et al.
Hum Vaccin Immunother. 9:1228-1233. 2013.GPC3ペプチドワクチン投与後に顕著な腫瘍壊死をきたした患者の免疫学的解析および病理解剖を含む組織学的解析について英文報告した。
52Repeatedly recurrent colon cancer involving the appendiceal orifice after endoscopic piecemeal mucosal resection: a case report.
Sekiguchi M, Matsuda T, Sekine S, Sakamoto T, Nakajima T, Kushima R, Akasu T, et al.
Korean J Gastroenterol. 61:286-289. 2013.
53 Risk factors for lymphatic and venous involvement in endoscopically resected gastric cancer.
Sekiguchi M, Sekine S, Oda I, Nonaka S, Suzuki H, Yoshinaga S, Taniguchi H, et al.
J Gastroenterol. 48:706-712. 2013.
54 Laser microdissection and two-dimensional difference gel electrophoresis reveals proteomic intra-tumor heterogeneity in colorectal cancer.
Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Fujita S, et al.
J Proteomics. 78:134-147. 2013.
55Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, et al.
Cancer Sci. 104:896-903. 2013.
56 Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels.
Suzuki T, Shibata T, Takaya K, Shiraishi K, Kohno T, Kunitoh H, Tsuta K, et al.
Mol Cell Biol. 33:2402-2412. 2013.
57 Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.
Takahashi A, Ishii G, Kinoshita T, Yoshida T, Umemura S, Hishida T, Yoh K, et al.
J Cancer Res Clin Oncol 139:1869-1878. 2013.高悪性度神経内分泌癌では、ポドプラニン陽性CFAsが、予後予測因子となることが示された。
58Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.
Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, et al.
J Biosci Bioeng 116:768-773. 2013.
59Macrophage migration inhibitory factor and stearoyl-CoA desaturase 1: Potential prognostic markers for soft tissue sarcomas based on bioinformatics analyses.
Takahashi H, Nakayama R, Hayashi S, Nemoto T, Murase Y, Nomura K, Takahashi T, et al.
PLoS One. 8:e78250. 2013.
60Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β.
Takahashi RU, Takeshita F, Honma K, Ono M, Kato K, Ochiya T.
Sci Rep. 3:2474. 2013.
61Estimation of the fraction of cancer cells in a tumor DNA sample using DNA methylation.
Takahashi T, Matsuda Y, Yamashita S, Hattori N, Kushima R, Lee YC, Igaki H, et al.
PLoS One. 8:e82302. 2013.
62Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3-5 cm in size.
Takahashi Y, Ishii G, Aokage K, Hishida T, Yoshida J, Nagai K.
Lung Cancer. 79:118-124. 2013.
6364 Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, et al.
J Nucl Med. 54:1869-1875. 2013.
64Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R, Sasajima Y, Tsuda H, Namikawa K, Tsutsumida A, Otsuka F, Yamazaki N.
Br J Dermatol. 168:1259-1266. 2013.
65The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.
Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, Watanabe S, et al.
Lung Cancer. 81:371-376. 2013.
66Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas.
Tsuta K, Mimae T, Nitta H, Yoshida A, Maeshima AM, Asamura H, Grogan TM, et al.
Hum Pathol. 44:975-982. 2013.
67Dome-type carcinoma of the colon masquerading a submucosal tumor.
Yamada M, Sekine S, Matsuda T.
Clin Gastroenterol Hepatol. 11:A30. 2013.
68Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in gastric cancer.
Yamanoi K, Fukuma M, Uchida H, Kushima R, Yamazaki K, Katai H, Kanai Y, et al.
Pathol Int. 63:13-19. 2013.
69Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis.
Yamazaki H, Mori T, Yazawa M, Maeshima AM, Matsumoto F, Yoshimoto S, Ota Y, et al.
Lab Invest. 93:1331-1338. 2013.
70ROS1-Rearranged Lung Cancer: Clinicopathologic and Molecular Study of 15 Surgical Cases.
Yoshida A, Kohno T, Tsuta K, Wakai S, Shimada Y, Arai Y, Asamura H, et al.
Am J Surg Pathol 37:554-562. 2013.
71Inflammatory myofibroblastic tumor of the lung with a novel isoform of PPFIBP1-ALK fusion gene.
Yoshida A, Shibata T, Tsuta K, Watanabe S, Tsuda H.
Histopathology. 63:881-883. 2013.
72Anaplastic lymphoma kinase (ALK) status in rhabdomyosarcoma.
Yoshida A, Shibata T, Wakai S, Ushiku T, Tsuta K, Fukayama M, Makimoto A, et al.
Mod Pathol. 26:772-781. 2013.
73Bile duct carcinoma involving the common channel associated with pancreaticobiliary maljunction shows an extension pattern similar to ductal carcinoma of the pancreas.
Yoshida N, Esaki M, Kishi Y, Shimada K, Ojima H, Kanai Y, Hiraoka N.
Pathol Int. 63:415-418. 2013.
74Solid Predominant Histology Predicts EGFR tyrosine-kinase inhibitor response in patients with EGFR Mutation-positive lung adenocarcinoma.
Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, et al.
J Cancer Res Clin Oncol 139:1691-1700. 2013.EGFR変異陽性肺腺癌の、初期耐性に関わる臨床病理像を解明した。
75Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation.
Zenke Y, Ishii G, Ohe Y, Kaseda K, Yoshida T, Matsumoto S, Umemura S, et al.
Pathol Int. 63:599-606. 2013.化学療法後の肺癌切除検体を用いて、予後予測因子の検討を行った。腫瘍細胞のALDH1陽性所見は、予後不良因子となった。

原著論文トップへ

2012年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H, Kanai Y.
Carcinogenesis. 33:1487-1493. 2012.腎細胞における1塩基解像度の高密度アレイによるDNAメチル化解析で、CpGアイランドにおけるDNAメチル化亢進が蓄積し、臨床病理学的に悪性度が高く、予後不良である、CpGアイランドメチル化形質 (CIMP)を同定し、腎細胞がん固有のCIMPマーカー遺伝子を同定した。
2DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma.
Arai E, Nakagawa T, Wakai-Ushijima S, Fujimoto H, Kanai Y.
Histopathology. 60:E12-E18. 2012.精巣Stage IセミノーマにおけるDNAメチルトランスフェラーゼ3Bの巣状発現が、非セミノーマへの悪性進展と予後の指標となることを示した。
3Smoking and genetic risk variation across populations of European, Asian, and African American ancestry--a meta-analysis of chromosome 15q25.
Chen LS, Saccone NL, Culverhouse RC, Bracci PM, Chen CH, Dueker N, Han Y, et al.
Genet Epidemiol. 36:340-351. 2012.
4Whole Genome Sequencing of Liver Cancers Identifies Etiological Influences on Mutation Patterns and Recurrent Mutations in Chromatin Regulators.
Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, et al.
Nat Genet. 44:760-764. 2012.様々な臨床背景を持ったh肝臓がんの全ゲノム解析
5Immunohistochemical profiling as a possible prognostic marker for patients with adenocarcinoma of unknown primary treated using platinum doublet chemotherapy.
Hashimoto K, Sasajima Y, Andoh M, Yonemori K, Hirakawa A, Furuta K, Tsuda H, et al.
PLoS One. 7:e31181. 2012.
6Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K.
Oncology 82:168-174. 2012.
7Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of CD204-positive macrophages to the tumor-promoting microenvironment.
Hirayama S, Ishii G, Nagai K, Ono S, Kojima M, Yamauchi C, Aokage K, et al.
J Thorac Oncol. 7:1790-1797. 2012.
8Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker.
Hosako M, Muto T, Nakamura Y, Tsuta K, Tochigi N, Tsuda H, Asamura H, et al.
J Proteomics. 75:833-844. 2012.悪性胸膜中皮腫と肺に発生しうる悪性腫瘍をプロテオーム解析で比較し、cathepsin Dが鑑別診断のためのバイオマーカーになりうることを免疫組織染色で見出した。
9Spinal astrocyte activation induced by neural invasion leads cancer cachexia in pancreatic cancer.
Imoto A, Mitsunaga S, Inagaki M, Aoyagi K, Sasaki H, Ikeda M, Nakachi K, et al.
Int J Cancer. 131:2795-2807. 2012.
10Prognostic significance of cancer associated stromal cells in stage I lung adenocarcinoma patients.
Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, Ochiai A.
Chest. 142:151-158. 2012.
11Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma.
Iwakawa R, Okayama H, Kohno T, Sato-Otsubo A, Ogawa S, Yokota J.
Genes Chromosomes Cancer. 51:462-472. 2012.267例の肺腺がん症例および非がん組織を対象とした全ゲノムコピー数解析の結果、近年がん抑制遺伝子として報告されているPARK2遺伝子が肺腺がんで失活する分子機序として肺細胞変異が大きく寄与していることを見い出した。
12DNA methylation alterations in human cancers. In: Tollefsbol T (ed), Epigenetics in Human Disease.
Kanai Y, Arai E.
Netherlands: Elsevier. pp29-52. 2012.諸臓器の前がん段階において、発がんの背景要因 (慢性炎症・ウイルスの持続感染・喫煙等)に呼応してエピゲノム異常が惹起されること、エピゲノム異常ががんの病態とよく相関することを概説した。
13Expression of a splicing variant of the CADM1 specific to small cell lung cancer.
Kikuchi S, Iwai M, Sakurai-Yageta M, Tsuboi Y, Ito T, Maruyama T, Tsuda H, et al.
Cancer Sci. 103:1051-1057. 2012.
14Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor.
Kikuta K, Kubota D, Saito T, Orita H, Yoshida A, Tsuda H, Suehara Y, et al.
J Proteomics. 75:1089-1098. 2012.ATP-dependent RNA helicase DDX39が消化管間質腫瘍において術後再発の高い相関を示すことをプロテオーム解析で見出し、同タンパク質が予後予測因子であることを免疫組織染色で明らかにした。
15Histologic and immunohistochemical analyses of α-fetoprotein--producing cancer of the stomach.
Kinjo T, Taniguchi H, Kushima R, Sekine S, Oda I, Saka M, Gotoda T, et al.
Am J Surg Pathol. 36:56-65. 2012.AFP産生胃がんの検討
16KIF5B-RET fusions in lung adenocarcinoma.
Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, et al.
Nat Med. 18:375-377. 2012.肺腺がんの新規治療標的としてRET融合遺伝子を発見した。1-2%に存在する融合陽性の肺がん患者は既存のRETキナーゼ阻害薬による治療の効果が見込まれる。
17Validation Study on Pfetin and ATP-dependent RNA Helicase DDX39 as Prognostic Biomarkers in Gastrointestinal Stromal Tumour.
Kubota D, Okubo T, Saito T, Suehara Y, Yoshida A, Kikuta K, Tsuda H, et al.
Jpn J Clin Oncol. 42:730-741 2012.消化管間質腫瘍の予後不良バイオマーカーpfetinの検証実験を行った。
18Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.
Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, Hosgood HD 3rd, et al.
Nat Genet. 44:1330-1335. 2012.
19Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status.
Maeshima AM, Tsuta K, Asamura H, Tsuda H.
Cancer. 118:4512-4518. 2012.肺内リンパ節転移の意義についての検討
20Hypomethylation of Alu repetitive elements in esophageal mucosa, and its potential contribution to the epigenetic field for cancerization.
Matsuda Y, Yamashita S, Lee YC, Niwa T, Yoshida T, Gyobu K, Igaki H, et al.
Cancer Causes Control. 23:865-873. 2012.
21FGFR2 gene amplification and clinicopathological features in gastric cancer.
Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, et al.
Br J Cancer. 106:727-732. 2012.
22Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.
Mimae T, Tsuta K, Kondo T, Nitta H, Grogan TM, Okada M, Asamura H, et al.
Ann Oncol. 23:3129-3137. 2012.胸腺腫瘍における遺伝子並びにタンパク異常の検討
23Cathepsin D as a potential prognostic marker for lung adenocarcinoma.
Mimae T, Tsuta K, Maeshima AM, Okada M, Asamura H, Kondo T, Tsuda H.
Pathol Res Pract. 208:534-540. 2012.カテプシンDが肺癌での予後因子であることの証明
24Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma.
Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, et al.
J Proteomics. 75:1577-1589. 2012.Macrophage-capping proteinが胆管がんのゲムシタビン抵抗症例において高発現していることをプロテオーム解析で見出し、同タンパク質が予後予測因子であることを免疫組織染色で明らかにした。
25Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.
Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, et al.
Cancer Sci. 103:233-238. 2012.
26A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, Singh S, et al.
Diagn Pathol. 7:60. 2012.
27Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, et al.
Int J Oncol. 40:63-70. 2012.肝細胞がんの外科切除後に対して、ラジオ波焼灼療法後の患者末梢血中にグリピカン3由来ペプチド特異的なCTLが増加することを示した。
28Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells.
Ohata H, Ishiguro T, Aihara Y, Sato A, Sakai H, Sekine S, Taniguchi H, et al.
Cancer Res. 72:5101-5110. 2012.
29Anal canal neuroendocrine carcinoma associated with squamous intraepithelial neoplasia: a human papillomavirus 18-related lesion.
Ohtomo R, Sekine S, Taniguchi H, Tsuda H, Moriya Y, Kushima R.
Pathol Int. 62:356-359. 2012.
30Identification of genes up-regulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.
Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, et al.
Cancer Res. 72:100-111. 2012.EGFR/KRAS/ALK遺伝子異常の陰性の肺がんの一部に遺伝子発現パターンで認識される予後不良の一群が存在することを見出した。この結果は、肺腺がん手術後の治療法選択に役立つ可能性がある。
31Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis.
Ono H, Hiraoka N, Lee YS, Woo SM, Lee WJ, Choi IJ, Saito A, et al.
Genes Chromosomes Cancer. 51:30-41. 2012.
32Prostate stem cell antigen gene is expressed in islets of pancreas.
Ono H, Yanagihara K, Sakamoto H, Yoshida T, Saeki N.
Anat Cell Biol. 45:149-154. 2012.
33Tumor-infiltrating lymphocytes (TIL) are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, et al.
Breast Cancer Res Treat. 132:793-805. 2012.乳がんにおける腫瘍内リンパ球の重要性
34Cytokewratin 7 is a predictive marker for survival in patients with esophageal squamous cell carcinoma.
Oue N, Noguchi T, Anami K, Kitano S, Sakamoto N, Sentani K, Uraoka N, et al.
Ann Surg Oncol. 19:1902-1910. 2012.
35Gasdermin superfamily: a novel gene family functioning in epithelial cells. In: Carrasco J and Mota M (eds), Endothelium and Epithelium: Composition, functions and pathology.
Saeki N, Sasaki H.
Nova Science Publishers. pp193-211. 2012.
36b-Catenin antagonizes PML tumor suppressor function by inhibiting SUMOylation and nuclear body formation.
Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I, Yamada T.
Gastroenterology. 142:572-581. 2012.
37Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma : immunologic evidence and potential for improving overall survival.
Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, et al.
Clin Cancer Res. 18:3686-3696. 2012.進行肝細胞がん患者を対象としたグリピカン3由来ペプチドワクチンのFIHのPhase I試験の報告で、免疫学的な効果を証明し、CTLが誘導された患者さんは予後が延ばせる可能性を示した。
38Identification of a DNA methylation marker that detects the presence of lymph node metastases of gastric cancers.
Shigematsu Y, Niwa T, Yamashita S, Taniguchi H, Kushima R, Katai H, Ito S, et al.
Oncol Lett. 4:268-274. 2012.
39A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population.
Shiraishi K, Kunitoh H, Daigo Y, Takahashi A, Goto K, Sakamoto H, Ohnami S, et al.
Nat Genet. 44:900-903. 2012.Genome-wide association studyの結果、17q24,3, 6q21,3上の2領域を新規の肺腺がん感受性領域として同定した。同領域に存在するBPTF遺伝子の発現量が遺伝子多型と関連することを見出した。
40Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer.
Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Sakamoto K, et al.
J Proteomics. 75:5342-5355. 2012.
41Serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of literature.
Togami S, Kasamatsu T, Sasajima Y, Onda T, Ishikawa M, Ikeda S, Kato T, et al.
Gynecol Obstet Invest. 73:26-31. 2012
42Clinicopathological and prognostic impact of human epidermal growth factor receptor 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.
Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, et al.
Cancer Sci. 103:926-932. 2012.
43c-MET/Phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, Tamura T, et al.
J Thorac Oncol. 7:331-339. 2012. Metタンパク発現並びに遺伝子増幅の肺腫瘍での検討
44Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.
Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, et al.
Genome Res. 22:208-219. 2012.
45Higher-order chromatin regulation and differential gene expression in the human tumor necrosis factor/lymphotoxin locus in hepatocellular carcinoma cells.
Watanabe T, Ishihara K, Hirosue A, Watanabe S, Hino S, Ojima H, Kanai Y, et al.
Mol Cell Biol. 32:1529-1541. 2012.
46Frequent activating GNAS mutations in villous adenoma of the colorectum.
Yamada M, Sekine S, Ogawa R, Taniguchi H, Kushima R, Tsuda H, Kanai Y.
J Pathol. 228:113-118. 2012
47Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma.
Yamaguchi T, Taniguchi H, Fujita S, Sekine S, Yamamoto S, Akasu T, Kushima R, et al.
Histopathology. 61:162-169. 2012.粘液産生大腸癌の臨床病理像の検討
48Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.
Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, Imoto S, et al.
PLoS One. 7:e43923. 2012.不死化ヒト肺上皮細胞のgefitinib存在下における培養によって139のgefitinib感受性遺伝子群を同定した。当センターの156例のStage I肺腺がん症例を用いた検証解析を行った結果、139遺伝子におけるハイリスク群が予後不良であることが確認された。
49NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma.
Yoshida A, Sekine S, Tsuta K, Fukayama M, Furuta K, Tsuda H.
Am J Surg Pathol. 36:993-999. 2012. NKX2,2の鑑別診断での有用性
50MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T.
Am J Surg Pathol. 36:423-431. 2012.MDM2, CDK4異常の骨肉腫での検討
51Loss of heterozygosity on chromosome 16q suggests malignancy in core needle biopsy specimens of intraductal papillary breast lesions.
Yoshida M, Tsuda H, Yamamoto S, Kinoshita T, Akashi-Tanaka S, Hojo T, Fukutomi T.
Virchows Arch. 460:497-504. 2012.16qの異常を乳管内乳頭腫での検討
52Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head.
Yoshikawa K, Mitsunaga S, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al.
Cancer Sci. 103:2012-2020. 2012.

原著論文トップへ

2011年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research.
Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura T, Hokamura N, Ashida A, et al.
PLoS One. 6:e18196. 2011.
2Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues.
Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, et al.
Pathobiology. 78:1-9. 2011.ゲノム網羅的DNAメチル化解析で、淡明細胞がん・乳頭状腎細胞がん・嫌色素細胞がん・オンコサイトーマ等の組織型と症例の予後を規定するDNAメチル化プロファイルが、腎の前がん段階で既に成立していることを示した。
3Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification.
Gotoh M, Arai E, Wakai-Ushijima S, Hiraoka N, Kosuge T Hosoda F, Shibata T, Kondo T, et al.
J Biomed Biotechnol. 2011:780836. Epub 2010.ゲノム網羅的DNAメチル化解析に基づき、膵液等に適用可能な膵癌の存在診断と、膵がん患者の予後診断の指標を開発した。
4Identification and validation of DNA methylation markers to predict lymph node metastasis of esophageal squamous cell carcinomas.
Gyobu K, Yamashita S, Matsuda Y, Igaki H, Niwa T, Oka D, Kushima R, et al.
Ann Surg Oncol. 18:1185-1194. 2011.
5Combined use of a solid-phase hexapeptide ligand library with liquid chromatography and two-dimensional difference gel electrophoresis for intact plasma proteomics.
Hagiwara T, Saito Y, Nakamura Y, Tomonaga T, Murakami Y, Kondo T.
Int J Proteomics. 2011:739615. 2011.
6Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney.
Ito H, Honda K, Satow R, Arai E, Shitashige M, Ono M, Sakuma T, et al.
Jpn J Clin Oncol. 41:847-853. 2011.
7MYC amplification as a prognostic marker of early stage lung adenocarcinoma identified by whole genome copy number analysis.
Iwakawa R, Kohno T, Kato M, Shiraishi K, Tsuta K, Noguchi M, Ogawa S, et al.
Clin Cancer Res. 17:1481-1489. 2011.MYCがん遺伝子の増幅が早期肺腺がんの予後因子となることを示した。この結果は、肺腺がん手術後の治療法選択に役立つ可能性がある。
8DNA methylation status in chronic liver disease and hepatocellular carcinoma.
Kanai Y, Arai E.
In: Wang XW, Grisham JW, Thorgeirsson S (eds), Molecular Genetics of Liver Neoplasia. New York: Springer. pp147-159. 2011.
9 Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.
Katori N, Sai K, Saito Y, Fukushima-Uesaka H, Kurose K Yomota C, Kawanishi T, Nishimaki-Mogami T, et al.
J Pharm Sci. 100:4546-4559. 2011.
10 Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cell carcinoma.
Kohno T, Kunitoh H, Mimaki S, Shiraishi K, Kuchiba A, Yamamoto S, Yokota J.
J Thorac Oncol. 6:813-817. 2011.
11 Hepatocyte nuclear factor 4A expression discriminates gastric involvement by metastatic breast carcinomas from primary gastric adenocarcinomas.
Koyama T, Sekine S, Taniguchi H, Tsuda H, Ikegami M, Hano H, Kushima R.
Hum Pathol. 42:1777-1784. 2011.
12 The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, et al.
Lung Cancer. 73:45-50. 2011.577例の肺腺がん症例を対象に、HRMA法と変異特異的IHC法とを用いてEGFRの変異の検出感度と特異性を検討した。その結果、IHC法はHRMA法に比して検出感度は劣るものの、有用であることを示した。
13Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.
Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T, Tsuda H, Hasegawa T, et al.
Jpn J Clin Oncol. 41:1194-1202. 2011.消化管間質腫瘍の予後不良バイオマーカーpfetinの検証実験を行った。
14Steroid receptor expression in thymomas and thymic carcinomas.
Mimae T, Tsuta K, Takahashi F, Yoshida A, Kondo T, Murakami Y, Okada M, et al.
Cancer. 117:4396-4405. 2011.
15Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, et al.
Br J Cancer. 105:131-138. 2011.胆道癌におけるMET癌遺伝子の発現と予後との関連
16Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis.
Muto T, Taniguchi H, Kushima R, Tsuda H, Yonemori H, Chen C, Sugihara Y, et al.
J Proteomics. 74:858-873. 2011.
17 Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage.
Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y.
Int J Cancer. 129:1170-1179. 2011.慢性肝炎・肝硬変症等慢性肝障害で経過観察中の患者における、DNAメチル化プロファイルに基づく、発がんリスク診断指標を開発した。
18Copy number alterations in urothelial carcinomas: Their clinicopathological significance and correlation with DNA methylation alterations.
Nishiyama N, Arai E, Nagashio R, Fujimoto H, Hosoda F, Shibata T, Tsukamoto T, et al.
Carcinogenesis. 32:462-469. 2011.尿路上皮がん検体においてSNPアレイを用いてゲノム構造異常を網羅的に解析し、エピゲノム異常とゲノム構造異常の双方が蓄積しながら、尿路の多段階発がん過程が進展することを示した。
19MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression.
Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, et al.
Mol Ther. 19:1123-1130. 2011.
20 Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein.
Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J, Tashiro F, et al.
J Biol Chem. 286:18251-18260. 2011.p53遺伝子多型ががん化と関わる分子機構を解明した
21 A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer.
Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, Chiku S, et al.
Gastroenterology. 140:892-902. 2011.
22The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts.
Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathé EA, et al.
Clin Cancer Res. 17:1875-1882. 2011.当センターからの肺腺がん症例191例を含めた317例の肺がん症例を対象としたマイクロRNAの発現解析の結果、miR-21の発現が、予後と関連することを示した。
23Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, et al.
J Thorac Oncol. 6:132-138. 2011.
24 Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma.
Sekine S, Ogawa R, Ojima H, Kanai Y.
Cancer Sci. 102:1742-1747. 2011.
25 Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.
Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki Y.
Am J Pathol. 178:1395-1402. 2011.悪性黒色腫におけるIDH1変異の報告
26 NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Shibata T, Kokubu A, Saito S, Narisawa-Saito N, Sasaki H, Aoyagi K, Yoshimatsu Y, et al.
Neoplasia. 13:864-873. 2011.食道がんにおけるNRF2癌遺伝子の変異と治療反応性との関連について示した
27 Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics.
Suehara Y, Tochigi N, Kubota D, Kikuta K, Nakayama R, Seki K, Yoshida A, et al.
J Proteomics. 74:829-842. 2011.SeceSecernin-1が滑膜肉腫の悪性度に関係することをプロテオーム解析で見出し、同タンパク質が予後予測因子であることを免疫組織染色で明らかにした。
28High-resolution characterization of a hepatocellular carcinoma genome.
Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsustumi S, et al.
Nat Genet. 43:464-469. 2011.HCV陽性肝臓がんの全ゲノム解読
29Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
Tsuta K, Tanabe Y, Yoshida A, Takahashi F, Maeshima AM, Asamura H, Tsuda H.
J Thorac Oncol. 6:1190-1199. 2011.
30Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma.
Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, et al.
Ann Surg Oncol. 18:2841-2850. 2011.
31Comprehensive histological analysis of ALK-rearranged lung carcinomas.
Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, et al.
Am J Surg Pathol. 35:1226-1234. 2011.
32 Bright-field dual color chromogenic insitu hybridization for diagnosing EML4-ALK-positive lung adenocarcinomas.
Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, Sekine I, Grogan TM, et al.
J Thorac Oncol. 6:1677-1686. 2011.
33Frequent ALK rearrangement and TTF-1/p63 co-expression of lung adenocarcinoma with signet-ring cell component.
Yoshida A, Tsuta K, Watanabe S, Sekine I, Fukayama M, Tsuda H, Furuta K, et al.
Lung Cancer. 72:309-315. 2011.

原著論文トップへ

2010年
No.論文名、演題名等著者、発表者等掲載誌、学会等成果又は特記事項
1Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma.
Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, Kanai Y, et al.
Am J Clin Pathol. 134:71-79. 2010.
2Detection of inappropriate samples in association studies by an IBS-based method considering linkage disequilibrium between genetic markers.
Andoh M, Sato Y, Sakamoto H, Yoshida T, Ohtaki M.
J Hum Genet. 55:436-440. 2010.
3DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status.
Arai E, Kanai Y.
Epigenomics. 2:467-481. 2010.多段階発がん過程の早期・前がん段階からDNAメチル化異常が寄与し、DNAメチル化プロファイルが、発がんリスク指標・病態診断・予後診断指標となることを示した。
4 Genetic and epigenetic alterations during renal carcinogenesis.
Arai E, Kanai Y.
Int J Clin Exp Pathol. 4:58-73. 2010.腎がんの諸組織型の病理組織学的・臨床病理学的特徴とゲノム・エピゲノム異常について概説した。
5 Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation.
Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, et al.
Br J Cancer. 103:1057-1065. 2010.
6 Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer.
Inoue M, Sano T, Kuchiba A, Taniguchi H, Fukagawa T, Katai H.
Br J Surg. 97:1056-1061. 2010.
7International network of cancer genome projects.
International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, et al.
Nature. 464:993-998. 2010.
8Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R, Kohno T, Enari M, Kiyono T, Yokota J.
Cancer Sci. 101:1891-1896. 2010.297例の肺腺がん症例を対象としたHPV16/18/33特異的PCR法を行った結果、陽性例は検出されなかった。この結果から、日本人における肺腺がん発がんにHPVは寄与する可能性は無い、あるいは稀であることを示した。
9 Genome-wide DNA methylation profiles in precancerous conditions and cancers.
Kanai Y.
Cancer Sci. 101:36-45. 2010.ゲノム網羅的DNAメチル化解析に基づき、肝・腎・膵・尿路等における多段階発がん過程経へのエピゲノム異常の寄与を概説した。
10Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities.
Kikuta K, Gotoh M, Kanda T, Tochigi N, Shimoda T, Hasegawa T, Katai H, et al.
Jpn J Clin Oncol. 40:60-72. 2010. 消化管間質腫瘍の予後不良バイオマーカーpfetinの検証実験を行った。
11Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics.
Kikuta K, Tochigi N, Saito S, Shimoda T, Morioka H, Toyama Y, Hosono A, et al.
Proteomics Clin Appl. 4:560-567. 2010.骨肉腫の術前化学療法の奏効性を予測する新規バイオマーカーperoxiredoxin2をプロテオーム解析で同定した。
12Reduced argininosuccinatesynthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.
Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, et al.
Mol Cancer Ther. 9:535-544. 2010.
13Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs.
Kohno T, Kakinuma R, Iwasaki M, Yamaji T, Kunitoh H, Suzuki K, Shimada Y, et al.
Carcinogenesis. 31:1794-1799. 2010.
14 Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes.
Kohno T, Kunitoh H, Shimada Y, Shiraishi K, Ishii Y, Goto K, Ohe Y, et al.
Carcinogenesis. 31:834-841. 2010.
15Genome-wide association study of pancreatic cancer in Japanese population.
Low S-K, Kuchiba A, Zembutsu H, Saito A, Takahashi A, Kubo M, Daigo Y, et al.
PLoS One. 5:e11824. 2010.
16Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, et al.
Mol Cell Proteomics. 9:695-704. 2010.
17Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M, Sugano K, Sugino H, Imai K, Matsumoto E, Maeda K, Fukuzono S, et al.
Cancer Sci. 101:250-258. 2010.
18CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, Nojima Y, et al.
Cancer Res. 70:5136-5146. 2010.
19 Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication.
Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, Oda I, et al.
J Gastroenterol. 45:37-44. 2010.
20Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, et al.
Cancer Sci. 101:1286-1291. 2010.大腸がん、腺腫とアディポサイトカインの関連についての検討。
21Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage.
Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, Shibata T, Kondo T, et al.
Cancer Sci. 101:231-240. 2010.尿路上皮がん・前がん段階にある尿路上皮・正常尿路上皮のゲノム網羅的DNAメチル化解析で、尿路上非がんの発生リスク診断・尿路上皮がんの再発予測・腎盂尿管がんの膀胱再発予測指標となるDNAメチル化プロファイルを同定した。
22 Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, et al.
Cancer Sci. 101:882-888. 2010.
23Prostate stem cell antigen: a Jekyll and Hyde molecule?
Saeki N, Gu J, Yoshida T, Wu X.
Clin Cancer Res. 16:3533-3538. 2010.
24 Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, et al.
Cancer Chemother Pharmacol. 66:95-105. 2010.
25Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, et al.
Br J Clin Pharmacol. 70:222-233. 2010.
26Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamouse cell carcinomas with extensive lymph node metastasis.
Sano M, Aoyagi K, Takahashi H, Kawamura T, Mabuchi T, Igaki H, Tachimori Y, et al.
Int J Oncol. 36:321-330. 2010.
27Biostatistic tools in pharmacogenomics--advances, challenges, potential.
Sato Y, Laird NM, Yoshida T.
Curr Pharm Des. 16:2232-2240. 2010.
28Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, et al.
Clin Cancer Res. 16:2518-2528. 2010.
29DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung.
Shibata T. Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, et al.
Oncogene. 29:4671-4681. 2010.肺小細胞がんにおけるDEKがん遺伝子の役割
30Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, et al.
J Clin Oncol. 28:4945-4952. 2010.640例の非小細胞肺がん症例を対象に27遺伝子上の30 SNPsのタイピングを行い、プラチナ製剤二剤併用治療に対する奏効性を検討した。さらに201症例、439症例の検証解析で、TP53,PARP1遺伝子のSNPが化学治療に対する奏効性と関連することを示した。
31Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth.
Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T, Ono M, et al.
Cancer Res. 70:5024-5033. 2010.
32 Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: Impact of genetic polymorphisms.
Sugiyama E, Kaniwa N, Kim S-R, Hasegawa R, Saito Y, Ueno H, Okusaka T, et al.
Clin Pharmacokinet. 49:549-558. 2010.
33Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.
Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, Ando M, et al.
Br J Cancer. 103:297-302. 2010.
34Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer.
Yamada Y, Arao T, Matsumoto K, Gupta V, Tan W, Fedynyshyn J, Nakajima TE, et al.
Cancer Sci. 101:1886-1890. 2010.
35 Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer.
Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, et al.
Cancer. 116:302-308. 2010.
36 Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, et al.
J Surg Oncol. 101:222-227. 2010.
37Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics.
Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, Tsuda H.
Mod Pathol. 23:1279-1288. 2010.
38 Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant.
Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H.
Am J Surg Pathol. 34:1361-1366. 2010.
39 Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: gastric cancer as an example.
Yoshida T, Ono H, Kuchiba A, Saeki N, Sakamoto H.
Cancer Sci. 101:1582-1589. 2010.

原著論文トップへ

ページトップへ